Details of the Drug Combination

General Information of Drug Combination (ID: DCU0FJ5)

Drug Combination Name
Simvastatin Idarubicin
Indication
Disease Entry Status REF
Glioblastoma? Investigative [1]
Component Drugs Simvastatin   DM30SGU Idarubicin   DMM0XGL
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: T98G
Zero Interaction Potency (ZIP) Score: 25.76
Bliss Independence Score: 25.76
Loewe Additivity Score: 10.67
LHighest Single Agent (HSA) Score: 10.67

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Simvastatin
Disease Entry ICD 11 Status REF
Arteriosclerosis BD40 Approved [2]
Atherosclerosis BD40 Approved [2]
Coronary heart disease BA80.Z Approved [2]
Cystic fibrosis CA25 Approved [2]
Depression 6A70-6A7Z Approved [2]
Hypercholesterolaemia 5C80.0 Approved [3]
Hyperlipidemia 5C80.Z Approved [2]
Hyperlipidemia, familial combined, LPL related N.A. Approved [2]
Hypertriglyceridemia 5C80.1 Approved [2]
Pneumonia CA40 Approved [2]
Primary hypercholesterolemia 5C80.00 Approved [2]
Prostate carcinoma N.A. Approved [2]
Rhinitis FA20 Approved [2]
Type-1/2 diabetes 5A10-5A11 Approved [2]
Stroke 8B20 Investigative [2]
Simvastatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [9]
------------------------------------------------------------------------------------
Simvastatin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [12]
------------------------------------------------------------------------------------
Simvastatin Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [13]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [14]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [15]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [16]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [17]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [14]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Metabolism [14]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Simvastatin Interacts with 264 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Activity [18]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [19]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Affects Response To Substance [20]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Increases Response To Substance [21]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Transport [22]
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Increases ADR [23]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Increases Response To Substance [24]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Decreases Response To Substance [25]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Decreases Activity [22]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [26]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Expression [26]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Activity [26]
Prostaglandin E synthase (PTGES) OTB7YQFU PTGES_HUMAN Decreases Expression [27]
Myeloperoxidase (MPO) OTOOXLIN PERM_HUMAN Decreases Expression [27]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Decreases Activity [27]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [27]
Advanced glycosylation end product-specific receptor (AGER) OTPY0IH7 RAGE_HUMAN Decreases Expression [27]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Decreases Expression [6]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Decreases Expression [6]
Cell division control protein 45 homolog (CDC45) OT6NNLOD CDC45_HUMAN Decreases Expression [6]
Integrin beta-like protein 1 (ITGBL1) OTJDHE17 ITGBL_HUMAN Decreases Expression [6]
Protein S100-A8 (S100A8) OTVMOB3F S10A8_HUMAN Increases Expression [6]
Integrin beta-1 (ITGB1) OT6G1IAR ITB1_HUMAN Decreases Expression [6]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [6]
Protein S100-A9 (S100A9) OTOARHCS S10A9_HUMAN Increases Expression [6]
Protein S100-A6 (S100A6) OTHHPZQ8 S10A6_HUMAN Increases Expression [6]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Decreases Expression [6]
Stromelysin-2 (MMP10) OTJDWW8Q MMP10_HUMAN Increases Expression [6]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Decreases Expression [6]
Annexin A3 (ANXA3) OTDD8OI7 ANXA3_HUMAN Decreases Expression [6]
Keratin, type I cytoskeletal 13 (KRT13) OTTYSKGX K1C13_HUMAN Increases Expression [6]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2) OTGVC9MY PLCG2_HUMAN Increases Expression [6]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Increases Expression [6]
Keratin, type I cytoskeletal 15 (KRT15) OTS6WLF7 K1C15_HUMAN Increases Expression [6]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [6]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [6]
Insulin-like growth factor-binding protein 6 (IGFBP6) OTW878VI IBP6_HUMAN Increases Expression [6]
Calmodulin-like protein 3 (CALML3) OTM8DNQU CALL3_HUMAN Increases Expression [6]
Gap junction beta-2 protein (GJB2) OTBKLEYB CXB2_HUMAN Increases Expression [6]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Decreases Expression [6]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) OTAYZZE6 AL3A1_HUMAN Increases Expression [6]
DNA replication licensing factor MCM4 (MCM4) OT19PNNG MCM4_HUMAN Decreases Expression [6]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [6]
Macrophage metalloelastase (MMP12) OT9Z7LHM MMP12_HUMAN Increases Expression [6]
Replication factor C subunit 5 (RFC5) OTAD79RT RFC5_HUMAN Decreases Expression [6]
Regulator of G-protein signaling 2 (RGS2) OT0FSRW7 RGS2_HUMAN Increases Expression [6]
Collagenase 3 (MMP13) OTY8BZIE MMP13_HUMAN Increases Expression [6]
DNA primase small subunit (PRIM1) OTWWP8Y6 PRI1_HUMAN Decreases Expression [6]
Cyclin-dependent kinase inhibitor 1C (CDKN1C) OTASTJ3Q CDN1C_HUMAN Increases Expression [6]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [6]
Collagen alpha-1(VII) chain (COL7A1) OT3MIRZJ CO7A1_HUMAN Increases Expression [6]
Keratin, type I cytoskeletal 17 (KRT17) OT6Y1DPK K1C17_HUMAN Increases Expression [6]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Increases Expression [6]
Focal adhesion kinase 1 (PTK2) OT3Q1JDY FAK1_HUMAN Decreases Activity [6]
Lymphotoxin-beta (LTB) OTUFS8CF TNFC_HUMAN Decreases Expression [6]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) OT4SO7J4 BNIP3_HUMAN Increases Expression [6]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Decreases Expression [6]
Centromere protein R (ITGB3BP) OT6Q7GR3 CENPR_HUMAN Decreases Expression [6]
Rho GTPase-activating protein 29 (ARHGAP29) OT8JH4TY RHG29_HUMAN Decreases Expression [6]
Interleukin-20 receptor subunit beta (IL20RB) OTHFXK95 I20RB_HUMAN Increases Expression [6]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [6]
Krueppel-like factor 6 (KLF6) OTQY9S7F KLF6_HUMAN Increases Expression [6]
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (PKMYT1) OTYRXD2T PMYT1_HUMAN Decreases Expression [6]
Cell division control protein 6 homolog (CDC6) OTX93FE7 CDC6_HUMAN Decreases Expression [6]
Spondin-2 (SPON2) OTE7JLNM SPON2_HUMAN Increases Expression [6]
Rac GTPase-activating protein 1 (RACGAP1) OTQE8IEH RGAP1_HUMAN Decreases Expression [6]
DNA replication factor Cdt1 (CDT1) OTVY53VG CDT1_HUMAN Decreases Expression [6]
Matrix metalloproteinase-28 (MMP28) OTHQZXM1 MMP28_HUMAN Increases Expression [6]
Alpha-catulin (CTNNAL1) OTESJ6JD CTNL1_HUMAN Decreases Expression [6]
Protein DBF4 homolog A (DBF4) OTBL7JHQ DBF4A_HUMAN Decreases Expression [6]
Krueppel-like factor 2 (KLF2) OTIP1UFX KLF2_HUMAN Increases Expression [6]
Catalase (CAT) OTHEBX9R CATA_HUMAN Increases Activity [28]
Sterol regulatory element-binding protein 1 (SREBF1) OTWBRPAI SRBP1_HUMAN Increases Localization [29]
NPC1-like intracellular cholesterol transporter 1 (NPC1L1) OT6GWW1P NPCL1_HUMAN Decreases Expression [30]
Signal transducer CD24 (CD24) OT7CODJ4 CD24_HUMAN Increases Expression [31]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Decreases Expression [31]
Killer cell immunoglobulin-like receptor 2DS2 (KIR2DS2) OTX31RLZ KI2S2_HUMAN Decreases Expression [31]
Killer cell lectin-like receptor subfamily F member 1 (KLRF1) OTGHZ7FU KLRF1_HUMAN Decreases Expression [31]
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK) OTLF4ZB1 IKKA_HUMAN Increases Phosphorylation [32]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Nitrosation [32]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Phosphorylation [32]
Methylenetetrahydrofolate reductase (MTHFR) OTUBJSR7 MTHR_HUMAN Increases Expression [33]
Sphingosine 1-phosphate receptor 1 (S1PR1) OTLTXDQT S1PR1_HUMAN Increases Expression [34]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Increases Expression [35]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [36]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Secretion [37]
Delta(24)-sterol reductase (DHCR24) OTP301JW DHC24_HUMAN Increases Expression [38]
Farnesyl pyrophosphate synthase (FDPS) OT6CKWV5 FPPS_HUMAN Increases Expression [39]
Squalene synthase (FDFT1) OTGDISIT FDFT_HUMAN Increases Expression [39]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Expression [40]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Expression [40]
Toll-like receptor 4 (TLR4) OTP7ML3S TLR4_HUMAN Increases Expression [41]
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) OTQ4W7MT TR11B_HUMAN Increases Expression [42]
Dynamin-1-like protein (DNM1L) OTXK1Q1G DNM1L_HUMAN Increases Expression [43]
Suppressor of cytokine signaling 7 (SOCS7) OT503VJG SOCS7_HUMAN Increases Expression [44]
Suppressor of cytokine signaling 3 (SOCS3) OTY183WJ SOCS3_HUMAN Increases Expression [44]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) OT9RDS3H IKKB_HUMAN Decreases Expression [45]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [46]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [47]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Expression [48]
Serine protease HTRA2, mitochondrial (HTRA2) OTC7616F HTRA2_HUMAN Affects Localization [43]
Alpha-actinin-4 (ACTN4) OTCNZAJ5 ACTN4_HUMAN Increases Expression [49]
E3 ubiquitin-protein ligase MARCHF6 (MARCHF6) OTBTA03N MARH6_HUMAN Increases Degradation [50]
Nephrin (NPHS1) OT21JD3P NPHN_HUMAN Increases Expression [49]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Increases Expression [41]
Apolipoprotein M (APOM) OTI3FQQC APOM_HUMAN Decreases Expression [51]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Decreases Expression [52]
Prothrombin (F2) OTNFSM49 THRB_HUMAN Decreases Activity [53]
Tissue-type plasminogen activator (PLAT) OTQPDNAB TPA_HUMAN Increases Expression [54]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Decreases Expression [55]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Decreases Expression [56]
GTPase KRas (KRAS) OT78QCN8 RASK_HUMAN Decreases Prenylation [57]
Platelet-derived growth factor subunit B (PDGFB) OTMFMFC3 PDGFB_HUMAN Decreases Activity [58]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Increases Expression [59]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Activity [60]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Increases Expression [44]
Interleukin-2 receptor subunit alpha (IL2RA) OT0MWCHG IL2RA_HUMAN Decreases Expression [44]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1) OTVVI3UI DQB1_HUMAN Affects Expression [61]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Decreases Expression [62]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Increases Expression [63]
Apolipoprotein A-I (APOA1) OT5THARI APOA1_HUMAN Increases Expression [64]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [65]
Alpha-fetoprotein (AFP) OT9GG3ZI FETA_HUMAN Increases Expression [66]
Transferrin receptor protein 1 (TFRC) OT8ZPBDL TFR1_HUMAN Affects Expression [41]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Increases Expression [67]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Decreases Secretion [68]
RAF proto-oncogene serine/threonine-protein kinase (RAF1) OT51LSFO RAF1_HUMAN Decreases Activity [69]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Expression [70]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [71]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Activity [72]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Decreases Activity [73]
Integrin beta-2 (ITGB2) OTEKPEPR ITB2_HUMAN Decreases Expression [74]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Increases Expression [44]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Decreases Expression [75]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL) OTG7J4BP PPBT_HUMAN Affects Expression [76]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [77]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Decreases Expression [78]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [74]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Decreases Localization [79]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Phosphorylation [80]
Thrombomodulin (THBD) OT8VHLKY TRBM_HUMAN Increases Expression [53]
Calpain-1 catalytic subunit (CAPN1) OTK6OQZR CAN1_HUMAN Increases Expression [81]
Heat shock protein HSP 90-alpha (HSP90AA1) OTLG1WPK HS90A_HUMAN Increases Expression [82]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Decreases Expression [83]
Rho-related GTP-binding protein RhoC (RHOC) OTOLE1FT RHOC_HUMAN Increases Expression [53]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Decreases Activity [84]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Increases Expression [85]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [86]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [43]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [77]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [87]
Osteopontin (SPP1) OTJGC23Y OSTP_HUMAN Decreases Expression [88]
Microtubule-associated protein tau (MAPT) OTMTP2Z7 TAU_HUMAN Affects Expression [89]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [81]
Cholesteryl ester transfer protein (CETP) OTAGPPOE CETP_HUMAN Decreases Expression [90]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [91]
Bone morphogenetic protein 2 (BMP2) OT23T37S BMP2_HUMAN Increases Expression [92]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [77]
C-C motif chemokine 5 (CCL5) OTSCA5CK CCL5_HUMAN Decreases Expression [93]
Tissue factor (F3) OT3MSU3B TF_HUMAN Decreases Expression [94]
HLA class I histocompatibility antigen, alpha chain E (HLA-E) OTX1CTFB HLAE_HUMAN Affects Expression [61]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Activity [95]
Indoleamine 2,3-dioxygenase 1 (IDO1) OT91DBN7 I23O1_HUMAN Increases Expression [96]
Ras-related C3 botulinum toxin substrate 2 (RAC2) OTAOHFNH RAC2_HUMAN Affects Localization [43]
CD44 antigen (CD44) OT9TTJ41 CD44_HUMAN Decreases Expression [71]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Phosphorylation [97]
Integrin beta-4 (ITGB4) OT28UK84 ITB4_HUMAN Increases Expression [53]
Cytotoxic T-lymphocyte protein 4 (CTLA4) OTYQR611 CTLA4_HUMAN Decreases Expression [44]
E-selectin (SELE) OT33RZWY LYAM2_HUMAN Decreases Expression [98]
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) OT0DH40W AL5AP_HUMAN Increases Expression [63]
Integrin alpha-L (ITGAL) OTCUQAIS ITAL_HUMAN Decreases Expression [74]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Increases Expression [96]
Tumor necrosis factor ligand superfamily member 4 (TNFSF4) OTOCBX7P TNFL4_HUMAN Decreases Expression [99]
Interleukin-4 receptor subunit alpha (IL4R) OTTXOTCW IL4RA_HUMAN Decreases Expression [44]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [91]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Decreases Expression [41]
CD27 antigen (CD27) OTH7NA58 CD27_HUMAN Decreases Expression [44]
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Increases Expression [100]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Activity [69]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Activity [69]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Increases Expression [101]
M-phase inducer phosphatase 2 (CDC25B) OT12MSRY MPIP2_HUMAN Affects Expression [102]
HLA class I histocompatibility antigen, alpha chain F (HLA-F) OT76CM19 HLAF_HUMAN Affects Expression [61]
Type-1 angiotensin II receptor (AGTR1) OT2NRMJP AGTR1_HUMAN Decreases Expression [103]
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Increases Activity [104]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [105]
Heat shock 70 kDa protein 4 (HSPA4) OT5HR0AR HSP74_HUMAN Increases Expression [82]
Nitric oxide synthase, inducible (NOS2) OTKKIOJ1 NOS2_HUMAN Increases Expression [106]
Myosin-10 (MYH10) OTXN2WXS MYH10_HUMAN Decreases Expression [56]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Activity [107]
C-C chemokine receptor type 2 (CCR2) OTQ7T10J CCR2_HUMAN Decreases Expression [108]
T-lymphocyte activation antigen CD86 (CD86) OTJCSBPC CD86_HUMAN Decreases Expression [41]
Signal transducer and activator of transcription 1-alpha/beta (STAT1) OTLMBUZ6 STAT1_HUMAN Decreases Expression [109]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [110]
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) OTDK74C0 TNR4_HUMAN Decreases Expression [99]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Decreases Expression [52]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [111]
CX3C chemokine receptor 1 (CX3CR1) OTIM9XT8 CX3C1_HUMAN Decreases Expression [112]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [113]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Expression [89]
Nuclear receptor ROR-gamma (RORC) OTUBFRPC RORG_HUMAN Decreases Expression [44]
C-C chemokine receptor type 5 (CCR5) OTP5FMZ4 CCR5_HUMAN Decreases Expression [93]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [114]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Decreases Activity [115]
Cyclin-dependent kinase 4 inhibitor D (CDKN2D) OT2TTZPZ CDN2D_HUMAN Increases Expression [91]
Ras-related C3 botulinum toxin substrate 3 (RAC3) OT2RE7A7 RAC3_HUMAN Affects Localization [43]
Transforming protein RhoA (RHOA) OT6YOJ9N RHOA_HUMAN Increases Expression [53]
Ras-related protein Rap-1A (RAP1A) OT5RH6TI RAP1A_HUMAN Decreases Expression [116]
Ras-related C3 botulinum toxin substrate 1 (RAC1) OTKRO61U RAC1_HUMAN Decreases Activity [69]
Rho GTPase-activating protein 4 (ARHGAP4) OTXV053R RHG04_HUMAN Increases Expression [53]
Cyclin-dependent kinase 5 (CDK5) OT1YAK9F CDK5_HUMAN Increases Expression [89]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Affects Localization [82]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Phosphorylation [117]
CD83 antigen (CD83) OT1V4WQF CD83_HUMAN Decreases Expression [41]
Myosin light chain 5 (MYL5) OT7CQ24K MYL5_HUMAN Increases Expression [63]
Caldesmon (CALD1) OTNJKJ6Q CALD1_HUMAN Decreases Expression [53]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [87]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [48]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Increases Expression [118]
Forkhead box protein O1 (FOXO1) OTPJRB6D FOXO1_HUMAN Decreases Localization [115]
TNF receptor-associated factor 2 (TRAF2) OT1MEZZN TRAF2_HUMAN Decreases Expression [45]
Nuclear factor of activated T-cells, cytoplasmic 3 (NFATC3) OTYOORME NFAC3_HUMAN Decreases Localization [119]
Myosin-binding protein H (MYBPH) OTQJBPUR MYBPH_HUMAN Increases Expression [63]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [48]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) OTXEE550 APR_HUMAN Increases Expression [43]
Bone morphogenetic protein receptor type-2 (BMPR2) OTM9W547 BMPR2_HUMAN Increases Stability [120]
Runt-related transcription factor 2 (RUNX2) OT97RQQM RUNX2_HUMAN Increases Expression [85]
Src substrate cortactin (CTTN) OTJRG4ES SRC8_HUMAN Affects Localization [53]
Squalene monooxygenase (SQLE) OT0GGRDO ERG1_HUMAN Decreases Degradation [50]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [121]
Interferon regulatory factor 4 (IRF4) OT1DHQ1P IRF4_HUMAN Decreases Expression [122]
Tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD) OTBOSJHO TRADD_HUMAN Decreases Expression [45]
Interleukin-17A (IL17A) OTY72FT2 IL17_HUMAN Decreases Expression [44]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Increases Expression [7]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [72]
Interleukin-27 subunit alpha (IL27) OTIS3OF8 IL27A_HUMAN Increases Expression [44]
Scavenger receptor class B member 1 (SCARB1) OTAE1UA1 SCRB1_HUMAN Increases Expression [123]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Decreases Phosphorylation [115]
Rho guanine nucleotide exchange factor 2 (ARHGEF2) OTBQTFRT ARHG2_HUMAN Increases Expression [53]
Interleukin-17F (IL17F) OT9W9DE0 IL17F_HUMAN Decreases Secretion [122]
Sphingosine 1-phosphate receptor 3 (S1PR3) OTXBIYO8 S1PR3_HUMAN Decreases Expression [123]
Mitogen-activated protein kinase kinase kinase 14 (MAP3K14) OTT3DOOL M3K14_HUMAN Decreases Expression [45]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [47]
Forkhead box protein P3 (FOXP3) OTA9Z9OC FOXP3_HUMAN Increases Expression [96]
Interleukin-22 (IL22) OTW31FU9 IL22_HUMAN Decreases Secretion [122]
Interleukin-21 (IL21) OTABCY4W IL21_HUMAN Decreases Expression [44]
Podocin (NPHS2) OTLCNUII PODO_HUMAN Increases Expression [49]
Interleukin-23 subunit alpha (IL23A) OTYO99HC IL23A_HUMAN Decreases Expression [44]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Affects Localization [43]
Dentin sialophosphoprotein (DSPP) OT1TYNDN DSPP_HUMAN Increases Expression [124]
7-dehydrocholesterol reductase (DHCR7) OTLILBUI DHCR7_HUMAN Affects Expression [76]
CD2-associated protein (CD2AP) OTC76KQM CD2AP_HUMAN Increases Expression [49]
Cytochrome b-245 light chain (CYBA) OT16N9ZO CY24A_HUMAN Affects Response To Substance [125]
5-hydroxytryptamine receptor 7 (HTR7) OT44DEWB 5HT7R_HUMAN Increases Response To Substance [126]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [37]
Leptin receptor (LEPR) OT9H7G0C LEPR_HUMAN Affects Response To Substance [127]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases ADR [23]
Small ribosomal subunit protein mS31 (MRPS31) OTB0OBWK RT31_HUMAN Decreases Response To Substance [128]
Neuropilin-1 (NRP1) OTCGULYV NRP1_HUMAN Decreases Response To Substance [128]
Sterol regulatory element-binding protein cleavage-activating protein (SCAP) OTCVXOD6 SCAP_HUMAN Affects Response To Substance [129]
Kinesin-like protein KIF6 (KIF6) OTDH3MR4 KIF6_HUMAN Increases ADR [130]
Collagen alpha-1(XIII) chain (COL13A1) OTM9IM6J CODA1_HUMAN Decreases Response To Substance [128]
5-hydroxytryptamine receptor 3B (HTR3B) OTMGIYRE 5HT3B_HUMAN Increases Response To Substance [126]
ELL-associated factor 2 (EAF2) OTSOET5L EAF2_HUMAN Decreases Response To Substance [128]
------------------------------------------------------------------------------------
⏷ Show the Full List of 264 DOT(s)
Indication(s) of Idarubicin
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [4]
Acute myeloid leukaemia 2A60 Approved [5]
Adult acute monocytic leukemia N.A. Approved [4]
Childhood acute megakaryoblastic leukemia N.A. Approved [4]
Leukemia N.A. Approved [4]
Idarubicin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [132]
------------------------------------------------------------------------------------
Idarubicin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [133]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [133]
------------------------------------------------------------------------------------
Idarubicin Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [134]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [134]
------------------------------------------------------------------------------------
Idarubicin Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Activity [131]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [135]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Increases Activity [131]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [136]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Decreases Activity [131]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [137]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Decreases Activity [131]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [138]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Activity [131]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Simvastatin FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2955).
4 Idarubicin FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
6 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
7 Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells. J Cardiovasc Pharmacol. 2008 Mar;51(3):267-73. doi: 10.1097/FJC.0b013e3181624b44.
8 Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide. Inflamm Res. 2012 May;61(5):485-91. doi: 10.1007/s00011-012-0435-9. Epub 2012 Jan 15.
9 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
10 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
12 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
13 A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
14 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
15 Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs. 2004;4(4):247-55.
16 In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997 Oct;25(10):1191-9.
17 Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.
18 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
19 Receptor-dependent regulation of the CYP3A4 gene. Toxicology. 2002 Dec 27;181-182:199-202.
20 Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol. 2007 Jan;47(1):87-93. doi: 10.1177/0091270006295063.
21 SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
22 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
23 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
24 Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res. 2007 Apr;55(4):310-7. doi: 10.1016/j.phrs.2006.12.009. Epub 2007 Jan 14.
25 Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008 Jul 22;118(4):355-62. doi: 10.1161/CIRCULATIONAHA.108.773267. Epub 2008 Jun 16.
26 Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
27 Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
28 The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006;63(9):738-42.
29 Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol. 2007 Oct 1;571(2-3):97-105.
30 Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis. 2008 May;198(1):198-207.
31 In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
32 Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
33 Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kappaB/iNOS. Cardiovasc Res. 2008 Oct 1;80(1):151-8.
34 Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb Haemost. 2008 Jul;100(1):119-26.
35 High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin. Am J Nephrol. 2009;30(2):99-111.
36 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
37 Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis. 2011 Dec;16(12):1268-84.
38 Simvastatin modulates the Alzheimer's disease-related gene seladin-1. J Alzheimers Dis. 2012;28(2):297-301.
39 Resveratrol potentiates effect of simvastatin on inhibition of mevalonate pathway in human endometrial stromal cells. J Clin Endocrinol Metab. 2013 Mar;98(3):E455-62.
40 Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
41 Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
42 [Effect of simvastatin on the function of MG63 cell line]. Shanghai Kou Qiang Yi Xue. 2010 Dec;19(6):658-62.
43 Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. Biochim Biophys Acta. 2010 Apr;1803(4):452-67. doi: 10.1016/j.bbamcr.2009.12.005. Epub 2010 Jan 4.
44 Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
45 Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J Immunol. 2007 Feb 15;178(4):2507-16. doi: 10.4049/jimmunol.178.4.2507.
46 Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
47 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
48 Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
49 Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int. 2006 Jul;70(1):177-86. doi: 10.1038/sj.ki.5001515. Epub 2006 May 17.
50 Cholesterol increases protein levels of the E3 ligase MARCH6 and thereby stimulates protein degradation. J Biol Chem. 2019 Feb 15;294(7):2436-2448. doi: 10.1074/jbc.RA118.005069. Epub 2018 Dec 13.
51 Effects of simvastatin on apolipoprotein M in vivo and in vitro. Lipids Health Dis. 2011 Jul 5;10:112. doi: 10.1186/1476-511X-10-112.
52 Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res. 2009 May 1;15(9):3076-83. doi: 10.1158/1078-0432.CCR-08-3004. Epub 2009 Apr 21.
53 Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol. 2004 May;30(5):662-70. doi: 10.1165/rcmb.2003-0267OC. Epub 2003 Nov 20.
54 Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering. Kidney Int. 2002 Nov;62(5):1611-9. doi: 10.1046/j.1523-1755.2002.00601.x.
55 Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. J Hypertens. 2008 Jun;26(6):1147-55. doi: 10.1097/HJH.0b013e3282f97dde.
56 Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
57 Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene. Jpn J Cancer Res. 1994 Jun;85(6):633-8. doi: 10.1111/j.1349-7006.1994.tb02406.x.
58 Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int. 1993 Sep;44(3):503-8. doi: 10.1038/ki.1993.274.
59 Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
60 Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J Mol Cell Cardiol. 2007 Aug;43(2):168-76. doi: 10.1016/j.yjmcc.2007.05.006. Epub 2007 May 18.
61 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
62 Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 2006 Apr;54(4):1298-308. doi: 10.1002/art.21723.
63 A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One. 2006 Dec 20;1(1):e97. doi: 10.1371/journal.pone.0000097.
64 Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 2002 Jul;163(1):59-68. doi: 10.1016/s0021-9150(01)00754-7.
65 Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004 Aug;44(2):180-5. doi: 10.1161/01.HYP.0000133310.42762.25. Epub 2004 Jun 7.
66 Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway. J Hepatol. 1999 May;30(5):904-10. doi: 10.1016/s0168-8278(99)80146-9.
67 The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J Korean Med Sci. 2005 Jun;20(3):438-44. doi: 10.3346/jkms.2005.20.3.438.
68 Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler Thromb Vasc Biol. 2007 May;27(5):1043-9. doi: 10.1161/ATVBAHA.107.139881. Epub 2007 Feb 15.
69 Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep. 2009 May;21(5):1317-22. doi: 10.3892/or_00000357.
70 Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 1999 Sep 15;84(6):655-9. doi: 10.1016/s0002-9149(99)00411-7.
71 Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem. 2011 Apr 1;286(13):11314-27. doi: 10.1074/jbc.M110.193714. Epub 2011 Jan 3.
72 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
73 Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
74 Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):397-403. doi: 10.1161/01.ATV.0000059384.34874.F0. Epub 2003 Jan 30.
75 Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Eur J Med Res. 2007 May 29;12(5):216-21.
76 Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. J Cell Mol Med. 2018 Feb;22(2):873-882. doi: 10.1111/jcmm.13373. Epub 2017 Oct 3.
77 Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
78 [Effect of simvastatin on endothelin-1 expression in endothelial cell cultured hypoxically]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Jan;39(1):72-5.
79 Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int. 2003 Jun;63(6):2065-74. doi: 10.1046/j.1523-1755.2003.t01-2-00004.x.
80 HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
81 [Simvastatin-induced apoptosis of K562 cells is mediated by endoplasmic reticulum stress]. Yao Xue Xue Bao. 2008 Apr;43(4):371-7.
82 Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
83 Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. 2008 Jul 25;372(2):356-61. doi: 10.1016/j.bbrc.2008.05.043. Epub 2008 May 19.
84 Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Hum Reprod. 2007 Apr;22(4):1161-7. doi: 10.1093/humrep/del464. Epub 2006 Dec 11.
85 The role of simvastatin in the osteogenesis of injectable tissue-engineered bone based on human adipose-derived stromal cells and platelet-rich plasma. Biomaterials. 2010 Jul;31(20):5325-35. doi: 10.1016/j.biomaterials.2010.03.037. Epub 2010 Apr 9.
86 Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci. 2010 Sep 11;41(1):118-24. doi: 10.1016/j.ejps.2010.05.021. Epub 2010 Jun 8.
87 Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol. 2007 Aug;58 Suppl 3:141-8.
88 Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep. 2011 Jan;25(1):41-7.
89 Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res. 2009 Oct;50(10):2095-102. doi: 10.1194/jlr.M900236-JLR200. Epub 2009 May 21.
90 Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans. Can J Clin Pharmacol. 1999 Summer;6(2):85-90.
91 Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010 Nov;26(5):735-41. doi: 10.3892/ijmm_00000520.
92 Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun. 2000 May 19;271(3):688-92. doi: 10.1006/bbrc.2000.2697.
93 Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia. Transplant Proc. 2006 Nov;38(9):2899-904. doi: 10.1016/j.transproceed.2006.08.136.
94 Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation. 2000 May 15;69(9):1830-6. doi: 10.1097/00007890-200005150-00017.
95 Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci. 2004 Apr;94(4):403-9. doi: 10.1254/jphs.94.403.
96 Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. Clin Exp Immunol. 2010 Aug;161(2):298-305. doi: 10.1111/j.1365-2249.2010.04170.x. Epub 2010 May 18.
97 Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
98 Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab. 2003 Nov;88(11):5341-7. doi: 10.1210/jc.2003-030724.
99 Simvastatin reduces OX40 and OX40 ligand expression in human peripheral blood mononuclear cells and in patients with atherosclerotic cerebral infarction. J Int Med Res. 2009 May-Jun;37(3):601-10. doi: 10.1177/147323000903700302.
100 Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2083-9. doi: 10.1161/01.ATV.0000096207.01487.36. Epub 2003 Sep 18.
101 Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005 Oct 15;172(8):987-93. doi: 10.1164/rccm.200501-041OC. Epub 2005 Jul 7.
102 Temporal gene expression analysis of human coronary artery endothelial cells treated with Simvastatin. Gene Expr. 2008;14(4):229-39. doi: 10.3727/105221608786883834.
103 Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin. J Cardiovasc Pharmacol. 2007 May;49(5):299-305. doi: 10.1097/FJC.0b013e31803d35ce.
104 Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005 Feb 28;133(2-3):197-203. doi: 10.1016/j.psychres.2004.11.005.
105 Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thromb Res. 2008;122(2):191-202. doi: 10.1016/j.thromres.2007.09.017. Epub 2007 Nov 26.
106 Mechanism of simvastatin-induced K562 cell apoptosis. Pharmacology. 2009;84(4):191-5. doi: 10.1159/000235907. Epub 2009 Sep 2.
107 Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells. Biocell. 2009 Aug;33(2):107-14.
108 HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation. 2005 Mar 22;111(11):1439-47. doi: 10.1161/01.CIR.0000158484.18024.1F.
109 Molecular mechanisms underlying the inhibition of IFN--induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J Cell Biochem. 2011 Feb;112(2):675-83. doi: 10.1002/jcb.22976.
110 [Effects of simvastatin on proliferation and apoptosis of acute monocytic leukemia cell line SHI-1]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Jun;19(3):612-6.
111 Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
112 [Effect of simvastatin on monocyte CX3CR1 expression in patients with acute coronary syndrome]. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Mar;28(3):475-7.
113 Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
114 Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab. 2010 Jul;95(7):3453-9. doi: 10.1210/jc.2010-0072. Epub 2010 Apr 28.
115 Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets. Transplantation. 2002 Oct 27;74(8):1063-9. doi: 10.1097/00007890-200210270-00001.
116 Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors. Cancer Res Commun. 2023 Dec 8;3(12):2497-2509. doi: 10.1158/2767-9764.CRC-23-0350.
117 HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J. 2005 Mar;19(3):476-8. doi: 10.1096/fj.04-2745fje. Epub 2004 Dec 29.
118 Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol. 2010 Apr 15;79(8):1200-9. doi: 10.1016/j.bcp.2009.12.007. Epub 2009 Dec 14.
119 Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells. Mol Neurobiol. 2010 Jun;41(2-3):384-91. doi: 10.1007/s12035-010-8122-8. Epub 2010 Apr 6.
120 Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochem Biophys Res Commun. 2006 Jan 6;339(1):59-64. doi: 10.1016/j.bbrc.2005.10.187. Epub 2005 Nov 8.
121 Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
122 Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. J Immunol. 2011 Sep 15;187(6):3431-7. doi: 10.4049/jimmunol.1100580. Epub 2011 Aug 19.
123 Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J Immunol. 2008 Nov 15;181(10):7332-40. doi: 10.4049/jimmunol.181.10.7332.
124 Simvastatin induces the odontogenic differentiation of human dental pulp stem cells in vitro and in vivo. J Endod. 2009 Mar;35(3):367-72. doi: 10.1016/j.joen.2008.11.024.
125 A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients. Clin Chim Acta. 2005 Oct;360(1-2):46-51. doi: 10.1016/j.cccn.2005.04.001.
126 Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007 Sep;36(3):329-35. doi: 10.1002/mus.20871.
127 Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men. Diabetes Res Clin Pract. 2003 Dec;62(3):169-75. doi: 10.1016/s0168-8227(03)00163-3.
128 NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. PLoS One. 2011 Apr 4;6(4):e18306. doi: 10.1371/journal.pone.0018306.
129 Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J. 2005;5(6):359-64. doi: 10.1038/sj.tpj.6500334.
130 Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29;51(4):435-43. doi: 10.1016/j.jacc.2007.05.057.
131 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
132 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
133 Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
134 In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
135 A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
136 The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52(5):430-4.
137 The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. Cell Mol Biol Lett. 2008;13(2):182-94. doi: 10.2478/s11658-007-0045-7. Epub 2008 Apr 10.
138 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.